ArticleScientific reports2025
A case report of bacteriophage therapy for the treatment of lung infection due to carbapenem-resistant Pseudomonas aeruginosa.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comparison and correlation of in vitro and in vivo approaches for determining Pseudomonas aeruginosa bacteriophages activity.BMC microbiology · 2026Article
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review
- Lipopolysaccharide-targeting treatments for multidrug-resistantExpert opinion on therapeutic targets · 2026Review
- The Role of Genomics in Advancing and Standardising Bacteriophage Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Phage therapy for multidrug-resistant pulmonary infections: bridging precision matching, lung delivery, host immunity, and clinical translation.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, with the increasing global antimicrobial resistance, bacteriophage therapy has emerged as one of the most promising alternatives to antibiotics. Numerous studies have reported the effectiveness and safety of phage therapy in treating multidrug-resistant bacterial infections. However, there is limited research on the relationship between the emergence of phage-resistant strains and clinical outcomes. In this study, we applied phage nebulization therapy to a patient with carbapenem-resistant Pseudomonas aeruginosa lung infection. After 8 weeks of treatment with P. aeruginosa phages, the patient's sputum bacterial load decreased, overall inflammatory markers decreased, and lung effusion significantly reduced despite isolation of phage-resistant strains. Whole-genome sequencing of resistant isolates, coupled with Galleria mellonella larvae infection modeling, revealed a trade-off effect, demonstrating attenuated virulence associated with phage resistance. This finding underscores the potential for phage therapy to achieve positive clinical outcomes even in the face of resistance development, highlighting the need for a nuanced understanding of phage-bacteria coevolution in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.